Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 8/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19369518 | 1.00 | MEN1 (0.37) | MEN1KMT2AGPR119NR1H2SRC | |
| SCHEMBL22126915 | 1.00 | MEN1 (0.37) | MEN1KMT2AGPR119NR1H2SRC | |
| SCHEMBL22126916 | 1.00 | MEN1 (0.37) | MEN1KMT2AGPR119NR1H2SRC | |
| SCHEMBL17328081 | 0.84 | SMN1; SMN2 (0.39) | GPR119NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL22943927 | 0.84 | NR1H2 (0.40) | GPR119NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL22117720 | 0.82 | ALDH1A1 (0.35) | MEN1KMT2ACHRM1ALDH1A1 | |
| SCHEMBL22117724 | 0.82 | ALDH1A1 (0.35) | MEN1KMT2ACHRM1ALDH1A1 | |
| SCHEMBL28640464 | 0.82 | ALDH1A1 (0.35) | MEN1KMT2ACHRM1ALDH1A1 | |
| SCHEMBL26537944 | 0.82 | NR1H2 (0.39) | GPR119NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL29170220 | 0.81 | CHRM2 (0.41) | MEN1KMT2ANR1H2SRCCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113473987-B | Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same | 细胞基因公司 | 2024-09-03 | — | — | CN | disclosed |
| US-11325889-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2022-05-10 | — | — | US | disclosed |
| CN-113473987-A | Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same | 细胞基因公司 | 2021-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325889-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | MEN1 2824/4885KMT2A 582/4885GPR119 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.